Clinical Trial Detail

NCT ID NCT01263951
Title Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

thyroid gland cancer

Therapies

Everolimus + Sorafenib

Age Groups: adult

No variant requirements are available.